0001209191-21-022557.txt : 20210323 0001209191-21-022557.hdr.sgml : 20210323 20210323162312 ACCESSION NUMBER: 0001209191-21-022557 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210319 FILED AS OF DATE: 20210323 DATE AS OF CHANGE: 20210323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arjona Ferreira Juan Camilo CENTRAL INDEX KEY: 0001714080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 21765048 MAIL ADDRESS: STREET 1: C/O MYOVANT SCIENCES INC. STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR CITY: BRISBANE STATE: CA ZIP: 94005 FORMER NAME: FORMER CONFORMED NAME: Ferreira Juan Camilo Arjona DATE OF NAME CHANGE: 20170807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 207-400-3351 MAIL ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-19 0 0001679082 Myovant Sciences Ltd. MYOV 0001714080 Arjona Ferreira Juan Camilo C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 0 1 0 0 Chief Medical Officer Common Shares 2021-03-19 4 M 0 7000 7.78 A 141535 D Common Shares 2021-03-19 4 S 0 7000 24.17 D 134535 D Stock Option (Right to Buy) 7.78 2021-03-19 4 M 0 7000 0.00 D 2028-04-15 Common Shares 7000 73550 D Shares sold pursuant to a 10b5-1 trading plan. The shares were sold at prices ranging from $24.01 to $24.42. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. /s/ Matthew Lang, Attorney-in-fact 2021-03-23